Vnitr Lek 2020, 66(1):28-33 | DOI: 10.36290/vnl.2020.005

Hepatotoxicity induced by bodybuilding supplements

Martina Jakabovičová, Zuzana Ďurkovičová, Tereza Hlavatá, Mária Szántová
III. interná klinika LF UK a UN, Nemocnica akademika Ladislava Dérera, Bratislava

Bodybuilding supplements are known as anabolic-androgenic steroids (AAS), as well as dietary supplements with their addition. Without medical indications, they are illegal but easily accessible and harmful, capable of causing various forms of liver damage from the transient increase in serum enzymes through acute cholestatic syndrome to the development of hepatic tumours in long-term use. The strongest hepatotoxic effects are associated with alkylated forms, although tumours have also been associated with unmodified or esterified testosterone. Since the 1980s, they have been widespread not only in top-level sport but also in the general population to improve athletic performance and body shaping. According to epidemiological studies, there has been an increase in their use in recent years. The paper provides an overview of the most common clinical forms of hepatotoxicity resulting from using AAS.

Keywords: anabolic‑androgenic steroids, herbal and dietary supplements (HDS), hepatocellular carcinoma, prolonged jandice, testosterone.

Published: February 21, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jakabovičová M, Ďurkovičová Z, Hlavatá T, Szántová M. Hepatotoxicity induced by bodybuilding supplements. Vnitr Lek. 2020;66(1):28-33. doi: 10.36290/vnl.2020.005.
Download citation

References

  1. Navarro V, Khan I, Bjornsson E. Liver Injury from Herbal and Dietary Supplements. Hepatology 2017; 65: 363-373. Go to original source... Go to PubMed...
  2. Navarro VJ, Barnhart H, Bonkovsky H et al. Liver Injury from Herbal and Dietary Supplements in the US Drug Induced Liver Injury Network. Hepatology 2014; 60: 1399-1408. Go to original source... Go to PubMed...
  3. Kolibáš E Anabolické steroidy - psychiatrická problematika ich zneužívania. Alkohol Drog Záv (Protialkohol Obz) 2004; 4-5: 217-235.
  4. Rahnema CD, Crosnoe LE, Kimed H. Designer steroids over the counter supplements and their androgenic component: review of an increasing problem. Andrology 2015; 3: 150-155. Go to original source... Go to PubMed...
  5. Maravelias C, Dona A, Stefanidou M et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett 2005; 158: 167-175. Go to original source... Go to PubMed...
  6. Barceloux DG, Palmer RB Anabolic‑androgenic steroids. Dis Mon 2013; 59: 226-248. Go to original source... Go to PubMed...
  7. Kanayama G, Hudson JI, Pope jr. HG Illicit anabolic androgenic steroid use. Horm Behav 2010; 58: 111-121. Go to original source... Go to PubMed...
  8. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic‑androgenic steroids. Clin Ther 2001; 23: 1355-1390. Go to original source... Go to PubMed...
  9. Szántová M Hepatotoxicita indukovaná herbálnou medicínou a dietetickými doplnkami. Interná med 2017; 17: 473-479.
  10. Caliz IM, Cortes MG, Jimenez AG. Herbal and Dietary Supplement‑Induced Liver Injuries in the Spanish DILI Registry. Clinic Gastroent and Hep 2018; 16: 1495-1502. Go to original source... Go to PubMed...
  11. Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on nonreproductive organs and functions. Rev Endocr Metab Disord 2015; 16: 199-211. Go to original source... Go to PubMed...
  12. Kabíček P. Zneužívaní anabolických steroidu u dospívajícich v medzinárodním kontextu. Vox pediatriae 2005; 5: 14-15.
  13. Eaton DK et al. Youth risk behavior surveillance - United States, 2007. Mortality and Morbidity Weekly Report. Surveillance Summaries 2008; 57: 1-131.
  14. Eisenberg ME, Wall M, Neumark‑Sztainer D. Muscle‑Enhancing Behaviors Among Adolescent Girls and Boys. Pediatrics 2012; 130: 1019-1036. Go to original source... Go to PubMed...
  15. Šimurka P, Zavrel M. Anabolické steroidy a mládež. Pediatr pro Praxi 2008; 9: 294-297.
  16. Snyder PJ. Androgens. In: Hardman JG, Limbird LE, Gilman AG (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill 2001; 1635-1648.
  17. Pope jr. HG, Wood RI, Rogol A et al. Adverse health consequences of performance‑enhancing drugs: an endocrine society scientific statement. Endocr Rev 2014; 35: 341-375. Go to original source... Go to PubMed...
  18. Andrade RJ, Lucena MI, Fernandez MC et al. Drug‑induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over 10-years period. Gastroenterology 2005; 129: 512-521. Go to original source... Go to PubMed...
  19. Szántová M, Sedlačko J, Jakabovičová M. Lieková a herbálna hepatotoxicita: Prehľad klinických klasifikácií. Vnitr lek 2018; 64: 384-393. Go to original source... Go to PubMed...
  20. Robles DM, Gonzalez JA, Medina CI. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther 2015; 41: 116-125. Go to original source... Go to PubMed...
  21. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 2006; 5: 104-109.Další literatura u autorky a na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
  22. Velazquez I, Alter BP Androgens and liver tumors: Fanconi's anemia and non‑Fanconi's conditions. Am J Hematol 2004; 77: 257-267. Go to original source... Go to PubMed...
  23. Bioulac‑Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-748. Go to original source... Go to PubMed...
  24. Schwingel PA, Cotrim HP, Salles BR et al. Anabolic‑androgenic steroids: a possible new risk factor of toxicant‑associated fatty liver disease. Liver Int 2011; 31: 348-353. Go to original source... Go to PubMed...
  25. Garcia CM, Robles DM, Ortega AA et al. Hepatotoxicity by dietary supplements: a tabular listing and clinical characteristics. Int J Mol Sci 2016; 17: 537. Go to original source... Go to PubMed...
  26. Ramachandran R, Kakar S Histological patterns in drug‑induced liver disease. J Clin Pathol 2009; 62: 481-492. Go to original source... Go to PubMed...
  27. Beuers U, Kremer AE, Bolier R et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014; 60: 399-407. Go to original source... Go to PubMed...
  28. Marino G, Zimmerman HJ, Lewis JH Management of drug‑induced liver disease. Curr Gastroentero Rep 2001; 3: 38-48. Go to original source... Go to PubMed...
  29. European Assoc Study L. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Jurnal of Hepatology 2009; 51: 237-267. Go to original source... Go to PubMed...
  30. Danan G, Teschke R RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci 2016; 17: 14. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.